May 15, 2024 – The Lancet Infectious Diseases published article on global burden associated with 85 pathogens in 2019. Helicobacter pylori (H. pylori) is the leading pathogen associated with disease burden in China.

This study estimated disability-adjusted life-years (DALYs) associated with 85 pathogens in 2019, globally, regionally, and for 204 countries and territories. Globally, an estimated 704 million DALYs were associated with 85 different pathogens, including 309 million (43·9% of the burden) in children younger than 5 years. This burden accounted for 27·7% (and 65·5% in those younger than 5 years) of the previously reported total DALYs from all causes in 2019. Three leading pathogens responsible for more than 50 million DALYs each in 2019 were tuberculosis (65·1 million), malaria (53·6 million), and HIV or AIDS (52·1 million). Substantial disease burden was associated with previously less recognized pathogens, including Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and H. pylori.

In China, H. pylori was associated with 7.21 million DALYs and was the leading pathogen for disease burden. The second to the fifth pathogens were hepatitis B virus, Staphylococcus aureus, Acinetobacter baumannii and Streptococcus pneumoniae, leading to 6.53 million, 3.76 million, 2.63 million and 2.16 million DALYs in China, respectively.

Link to the article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00158-0/fulltext.

特别申明：文章原引内容及涉及字体图片等素材版权归原作者所有。本文章内容仅用于学习及学术交流，不做任何商业用途。

About TenNor Therapeutics

TenNor Therapeutics (6872.HK), incorporated in 2013, is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of June 30, 2026, TenNor Therapeutics had built a pipeline of eight innovative programs, including two Core Products, namely: rifasutenizol (TNP-2198), a multi-targeted conjugated new molecular entity (“NME”) candidate for the treatment of Helicobacter pylori infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and Clostridioides difficile (C. difficile) infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infection and implant-associated bacterial infections (such as prosthetic joint infection, left ventricular assist device infection and catheter-related bloodstream infection).

For more information, please visit: www.tennortherapeutics.com